Physician profile
Jun Ho Lee
NPI 1508252743
$3,191.88
in general payments reported to CMS, 2019-2025
18 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.29 · 2021: $55.39 · 2022: $354 · 2023: $700 · 2024: $676 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.45 |
| Education | $162.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.02 | 2022-2025 | |
| Amgen INC. | $613.34 | 2022-2025 | Enbrel, Tavneos, Evenity |
| Novartis Pharmaceuticals Corporation | $579.94 | 2022-2025 | |
| Ucb, INC. | $320.91 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $248.25 | 2023-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $195.72 | 2023-2025 | Saphnelo |
| Organon LLC | $100.16 | 2022-2025 | Hadlima |
| Horizon Therapeutics Plc | $74.26 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $59.42 | 2020-2025 | Orencia |
| Glaxosmithkline, LLC. | $57.78 | 2023-2025 | Benlysta, Nucala |
| Invivyd INC | $50.52 | 2025 | Pemgarda |
| Mallinckrodt Hospital Products INC. | $50.16 | 2024-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $48.28 | 2025 | Lupkynis |
| Genzyme Corporation | $47.91 | 2023-2025 | |
| Pfizer INC. | $29.30 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.76 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.54 | 2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.